» Articles » PMID: 23112807

Can We Vaccinate Against Type 1 Diabetes?

Overview
Journal F1000 Biol Rep
Specialty Biology
Date 2012 Nov 1
PMID 23112807
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccination is the administration of antigenic material to stimulate the immune system to develop adaptive immunity to a disease. As the most successful prophylactic in medical history, there is now an emerging interest as to whether vaccination can be applied in autoimmune and inflammatory conditions. These are diseases of failed immune regulation; vaccination in this context aims to exploit the power of antigenic material to stimulate immune homeostasis in the form of active, adaptive, regulatory immune responses. Type 1 diabetes is an autoimmune disease that could benefit from the therapeutic potential of vaccination. The major conditions necessary to make prophylaxis feasible are in place; the self antigens are known, the failure of existing immune regulation has been demonstrated, early studies of vaccine approaches have proved safe, and the preclinical prodrome of the disease can be easily detected by simple blood tests. Challenges for future implementation include finding the best mode of delivery and the best blend of adjunctive therapies that create the favorable conditions required for a vaccine to be effective.

Citing Articles

The Story of NAIMIT - A Framework 7 Project on Type 1 Diabetes.

Mathieu C, Overbergh on behalf of the NAIMIT consortium L Eur Endocrinol. 2018; 10(2):100-105.

PMID: 29872472 PMC: 5983077. DOI: 10.17925/EE.2014.10.02.100.


Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes".

Daniel C, Weigmann B, von Boehmer H J Exp Med. 2017; 214(7):2157-2159.

PMID: 28536240 PMC: 5501570. DOI: 10.1084/jem.20170285.


Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform.

Gottlieb P, Utz P, Robinson W, Steinman L Clin Immunol. 2013; 149(3):297-306.

PMID: 24094739 PMC: 4800754. DOI: 10.1016/j.clim.2013.08.010.

References
1.
Larche M, Akdis C, Valenta R . Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006; 6(10):761-71. DOI: 10.1038/nri1934. View

2.
Wherrett D, Bundy B, Becker D, DiMeglio L, Gitelman S, Goland R . Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011; 378(9788):319-27. PMC: 3580128. DOI: 10.1016/S0140-6736(11)60895-7. View

3.
Karges W, Pechhold K, Al Dahouk S, Riegger I, Rief M, Wissmann A . Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7.1 mice. Diabetes. 2002; 51(11):3237-44. DOI: 10.2337/diabetes.51.11.3237. View

4.
DCruz L, Klein L . Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005; 6(11):1152-9. DOI: 10.1038/ni1264. View

5.
Peakman M, Dayan C . Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?. Immunology. 2002; 104(4):361-6. PMC: 1783327. DOI: 10.1046/j.1365-2567.2001.01335.x. View